IMOJEV

BIOLOGICAL4 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, University of Liverpool, Singapore General Hospital, SK Bioscience Co., Ltd.

Conditions

Infectious DiseaseJapanese EncephalitisJapanese Encephalitis Virus DiseaseViral InfectionYellow Fever

Phase 1

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

RecruitingNCT06680128

SK Bioscience Co., Ltd.Japanese Encephalitis Virus Disease

Start: 2025-02-24End: 2028-03-19Target: 402Updated: 2025-12-23

Phase 2

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Singapore General HospitalInfectious Disease, Japanese Encephalitis, Viral Infection +1

Start: 2022-09-28End: 2025-10-31Target: 70Updated: 2023-04-12

Phase 3

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

CompletedNCT01900444

Sanofi Pasteur, a Sanofi CompanyJapanese Encephalitis

Start: 2013-07-11End: 2014-03-11Updated: 2022-03-28

Unknown Phase

Flavivirus Cross-priming Potential of IMOJEV

CompletedNCT03920111

University of LiverpoolJapanese Encephalitis

Start: 2021-04-16End: 2022-05-11Updated: 2025-01-31

Related Papers

Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.

2025-01-1022 citations

An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial

Frontiers in Immunology2023-03-104 citations